What Is Wegovy® and How Is It Different From Other GLP-1s?

What Wegovy® Is and Why It Exists

Wegovy® is a subcutaneous, once-weekly injection of semaglutide at a 2.4 mg maintenance dose. The FDA granted it a distinct approval from Ozempic specifically for chronic weight management, a label that allows physicians to prescribe it to patients who have obesity or overweight with a qualifying comorbidity but who may not have type 2 diabetes.

The GLP-1 Receptor Agonist Mechanism

GLP-1 (glucagon-like peptide-1) is an incretin hormone released from intestinal L-cells after eating. GLP-1 receptor agonists like semaglutide mimic this hormone at pharmacological concentrations. Three effects drive weight loss: delayed gastric emptying, suppression of glucagon, and a direct action on hypothalamic appetite centers that reduces hunger and increases the sensation of fullness [1].

At the 2.4 mg dose studied in the STEP program, these central appetite effects appear stronger than those observed at the 0.5 mg and 1 mg doses used in Ozempic for glucose control. The dose-response relationship for weight loss with semaglutide is well-documented in the STEP-5 trial (N=304), which showed 15.2% mean weight loss at 104 weeks with 2.4 mg vs. 2.6% with placebo [2].

Why the FDA Created a Separate Approval

Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) was approved in December 2017 for glycemic control in type 2 diabetes and later for cardiovascular risk reduction. Prescribing it off-label for weight loss alone is technically permitted but places clinicians in a gray zone regarding patient selection, dosing, and insurance reimbursement. Wegovy's dedicated obesity approval gives providers a cleaner clinical and regulatory pathway [3].

How Wegovy® Compares to Ozempic

Both drugs contain semaglutide. The active molecule, the injection device design, and the weekly schedule are identical. The differences are dose, labeled indication, and pen device.

Dose Differences

Ozempic tops out at 2 mg for diabetes management. Wegovy escalates to 2.4 mg over a 16-week titration schedule: 0.25 mg for weeks 1-4, 0.5 mg for weeks 5-8, 1.0 mg for weeks 9-12, 1.7 mg for weeks 13-16, then 2.4 mg maintenance. This structured ramp is designed to minimize gastrointestinal side effects before reaching the higher therapeutic dose [4].

Clinical Outcomes at Each Dose

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% for placebo, with 86.4% of participants achieving at least 5% weight loss [5]. By comparison, semaglutide 1 mg in the SUSTAIN-6 trial showed modest weight changes (approximately 4.3 kg) as a secondary endpoint in a diabetes cohort, illustrating how the higher dose unlocks substantially greater adipose-specific pharmacology.

Pen Device and Insurance Coverage

Wegovy and Ozempic use different pre-filled pen injectors and have different National Drug Codes. Insurers treat them as separate products. Patients who receive Ozempic under a diabetes benefit may not be covered when switching to Wegovy under an obesity benefit, and vice versa. This creates real-world access gaps that providers need to anticipate.

How Wegovy® Compares to Saxenda® (Liraglutide 3 mg)

Saxenda was the first GLP-1 approved for chronic weight management (December 2014) and remained the benchmark until Wegovy arrived. The comparison matters clinically because some patients tolerate one better than the other, and payers may require a Saxenda trial before authorizing Wegovy.

Molecule and Injection Frequency

Saxenda uses liraglutide, a GLP-1 analogue with a 13-hour half-life that requires daily injections. Wegovy uses semaglutide, which has a half-life of approximately 165 hours, enabling once-weekly dosing. Weekly dosing is associated with better real-world adherence in chronic disease settings, though head-to-head adherence data between the two products specifically are limited.

Weight Loss Efficacy

The SCALE Obesity and Prediabetes trial (N=3,731) found liraglutide 3 mg produced 8.0% mean body weight loss at 56 weeks vs. 2.6% placebo [6]. Wegovy's 14.9% at 68 weeks in STEP-1 is a substantially larger effect, though no direct randomized comparison exists between the two products. Cross-trial comparisons carry significant methodological caveats, including different follow-up durations and baseline characteristics.

Side Effect Profile

Both agents share nausea, vomiting, diarrhea, and constipation as the most common adverse effects. Saxenda's daily dosing means patients experience peak plasma concentrations more frequently, which some patients report as more persistent nausea. Pancreatitis, thyroid C-cell tumor risk (based on rodent data), and gallbladder disease warnings appear on both labels [3][6].

How Wegovy® Compares to Mounjaro® and Zepbound® (Tirzepatide)

Tirzepatide is the newest approved agent in this class and represents a fundamentally different pharmacological approach. Understanding the distinction helps patients and clinicians choose the right agent.

Dual vs. Single Receptor Agonism

Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second incretin hormone. Activating both receptors appears to produce additive or synergistic effects on adipose tissue lipolysis and hypothalamic satiety signaling. Semaglutide activates only the GLP-1 receptor.

Mounjaro (tirzepatide 2.5-15 mg) carries FDA approval for type 2 diabetes (May 2022). Zepbound (tirzepatide 2.5-15 mg) carries the distinct obesity approval (November 2023), mirroring the Ozempic/Wegovy split seen with semaglutide [7].

Weight Loss Comparison

The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean body weight loss at 72 weeks vs. 3.1% placebo, with 57.8% of participants achieving at least 20% body weight reduction [8]. Wegovy's STEP-1 showed 14.9% at 68 weeks with 32.0% of participants reaching at least 15% weight loss.

No head-to-head randomized controlled trial between semaglutide 2.4 mg and tirzepatide 15 mg has been published. The SURMOUNT and STEP programs used different eligibility criteria, so numeric comparisons should be made carefully.

Which Drug Is Right for Which Patient

The following framework reflects the HealthRX medical team's clinical approach to GLP-1 agent selection, based on published efficacy data, FDA label criteria, payer access patterns, and tolerability considerations. It is intended as a starting point for shared decision-making, not a replacement for individualized clinical judgment.

| Clinical scenario | Preferred first-line consideration | |---|---| | Overweight/obesity, no T2DM, insurer requires step therapy | Saxenda (liraglutide 3 mg) first, then Wegovy | | Overweight/obesity, no T2DM, first-line access | Wegovy (semaglutide 2.4 mg) | | Obesity plus T2DM, primary goal: glycemic control | Ozempic (semaglutide 1-2 mg) or Mounjaro (tirzepatide) | | Obesity plus T2DM, primary goal: maximum weight loss | Zepbound (tirzepatide 2.4-15 mg) or Wegovy | | Established cardiovascular disease, obesity, no T2DM | Wegovy (SELECT trial cardiovascular data available) | | Patient with prior GLP-1 nausea, wants weekly option | Wegovy with slower personal titration |

Payer formulary position and prior authorization requirements should always be verified before initiating any of these agents.

Wegovy's Cardiovascular Outcome Data: A Key Differentiator

For patients with established cardiovascular disease, Wegovy holds a specific advantage over most other weight-loss drugs: the SELECT trial.

The SELECT Trial

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) enrolled 17,604 adults aged 45 or older with pre-existing cardiovascular disease, a BMI of at least 27, and no history of diabetes. Participants were randomized to semaglutide 2.4 mg or placebo on top of standard care and followed for a mean of 39.8 months.

Wegovy reduced major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) by 20% vs. Placebo (hazard ratio 0.80; 95% CI 0.72-0.90; P<0.001) [9]. This was the first trial to show a weight-loss drug reducing hard cardiovascular endpoints in a non-diabetic population.

The FDA updated Wegovy's label in March 2024 to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. No other dedicated weight-management GLP-1 currently carries this specific cardiovascular outcomes label.

What SELECT Means for Prescribers

As the American Heart Association noted in its 2024 guidance update, "the SELECT data support treating obesity as a cardiovascular risk factor amenable to pharmacotherapy, not just lifestyle intervention." Prescribers caring for patients with heart disease and a BMI of 27 or higher now have a regulatory and evidence basis to initiate Wegovy as part of a cardiovascular risk reduction strategy, not merely a weight loss strategy.

Who Qualifies for Wegovy®

The FDA-approved indication covers adults with:

• A BMI of 30 or higher (obesity), or
• A BMI of 27 or higher (overweight) plus at least one weight-related comorbidity: hypertension, type 2 diabetes mellitus, or dyslipidemia [3]

Wegovy was also approved in December 2022 for adolescents aged 12 and older with an initial BMI at or above the 95th percentile for age and sex, based on data from the STEP Teens trial (N=201), which showed 16.1% mean BMI reduction at 68 weeks vs. 0.6% placebo [10].

Contraindications

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, patients with Multiple Endocrine Neoplasia syndrome type 2, and those who are pregnant. It should be used with caution in patients with a history of pancreatitis or severe gastrointestinal disease [3].

Dose Titration Schedule

The 16-week escalation is not optional. Skipping the ramp-up to minimize nausea and vomiting is associated with higher rates of discontinuation. Patients who miss a dose by more than five days should skip that dose and resume their next scheduled injection. If more than two consecutive doses are missed at the 2.4 mg maintenance level, some clinicians restart titration from a lower dose, though label guidance specifically addresses this scenario by recommending resumption at the last tolerated dose [3].

Real-World Effectiveness and Discontinuation Rates

Clinical trial populations are typically more adherent than community patients. A 2023 retrospective analysis of 3,389 commercially insured adults initiating Wegovy found that only 31.5% of patients remained on therapy at 12 months, with gastrointestinal side effects and cost as the two most commonly cited discontinuation reasons [11].

Maintaining Weight Loss After Stopping

The STEP-4 trial (N=803) demonstrated that patients who achieved weight loss on semaglutide 2.4 mg and then switched to placebo regained two-thirds of lost weight within 48 weeks [12]. This finding underscores that GLP-1 therapy requires ongoing use to maintain results, a consideration that directly informs how Wegovy should be framed in shared decision-making conversations.

Weight regain after discontinuation is not unique to Wegovy; it reflects the chronic, relapsing nature of obesity as a condition with persistent neuroendocrine dysregulation. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Weight loss medications should be used as part of a long-term treatment plan, with the expectation that ongoing pharmacotherapy will be needed to sustain outcomes" [13].

Cost, Access, and Compounded Semaglutide

Wegovy's list price is approximately $1,349 per month without insurance. With Novo Nordisk's savings card, commercially insured patients may pay as little as $25/month, though eligibility requirements apply and the card is unavailable for Medicare and Medicaid beneficiaries.

Insurance Coverage Realities

Most commercial plans now cover Wegovy for obesity, but many require documentation of a qualifying BMI, evidence of prior behavioral intervention, and sometimes a failed trial of Saxenda or another agent. Medicare Part D plans were prohibited from covering weight loss drugs until the Treat and Reduce Obesity Act provisions were included in recent budget discussions; as of mid-2025, coverage expansion for Medicare beneficiaries remains in flux.

Compounded Semaglutide

During 2022-2024, semaglutide was on the FDA's drug shortage list, permitting compounding pharmacies to prepare semaglutide-based formulations. The FDA removed semaglutide from the shortage list in February 2025, triggering enforcement action against most compounders. Compounded semaglutide products are not FDA-approved, may not contain the same salt form or purity as Wegovy, and lack the clinical trial data supporting the branded product [14]. Patients currently using compounded versions should discuss transitioning to the branded drug with their prescriber.